(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 28 July 2005 (28.07.2005)

PCT

(10) International Publication Number WO 2005/067932 A1

- (51) International Patent Classification⁷: A61K 31/498, 31/4985, C07D 413/12, 403/12, 417/12, 409/12, 407/12, 471/04, 241/44, A61P 3/10
- (21) International Application Number:

PCT/US2004/043409

(22) International Filing Date:

22 December 2004 (22.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/534,534

6 January 2004 (06.01.2004) US

- (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA, N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BEAVERS, Mary, Pat [US/US]; 2581 Aquetong Road, New Hope, Pennsylvania 18938 (US). DUDASH, Joseph [US/US]; 51 Taurus Drive, Unit 1A, Hillsborough, New Jersey 08844 (US). ZHANG, Yongzheng [US/US]; 5 Stockton Road, Hillsborough, New Jersey 08844 (US).


- (74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY



(57) Abstract: The invention features pharmaceutically active quinoxalinones of formula (1), compositions containing them, and methods of making and using theme: Formula (I) wherein R^1 is H, C $_{1-6}$ alkyl, or halo; R^2 is H or halo; R^3 is H, C $_{1-6}$ alkyl, X is N or CH; Y is a covalent bond, -NHCO- or -CONH-; Z is phenyl or a 5 or 6-membered heterocyclyl with between 1 and 2 heteroatoms independently selected from N, O, and S; and n is 0, 1 or 2; or a pharmaceutically acceptable salt, ester, amide, hydrate, or solvate thereof; as well as their use as glycogen phosphorylase inhibitors for the treatment of i diabetes and obesity.

PRD-2174

(3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY

Background of the Invention

5

10

15

20

25

30

Non-insulin dependent diabetes mellitus (NIDDM) is a polygenic disease characterized by defects in the action of insulin on numerous target tissues including muscle, adipose, and liver. It is well established that normal glucose homeostasis requires precise metabolic control in all of the insulin-responsive tissues; however, the relative importance of each of these tissues to the pathogenesis of NIDDM remains unclear.

More specifically, maintenance of normal glucose homeostasis involves a series of highly orchestrated events mediated by numerous cellular proteins including those which catalyze 1) the transport and phosphorylation of glucose, 2) the assembly of glycogen from the phosphorylated glucose monosaccharide, and 3) glycogenolysis and hepatic glucose production. Each of these processes represents a possible site for therapeutic intervention. There are several pathways that regulate hepatic glucose production (HGP) relating to the regulation of circulating blood glucose levels in NIDDM. Since hepatic glucose production is significantly increased in Type II diabetic patients relative to non-diabetics Consoli, A. (1992) Diabetes Care 15: 430-44, Gerich J.E. (1992) Horm. Metab. Res. 26: 18-21, agents which reduce hepatic glucose output should be beneficial for the treatment of diabetes. Moreover, it has been shown that after a meal, normal suppression of HGP is not observed in Type II diabetics (Gerich, 1992). Therefore, it appears that unregulated hepatic glucose production in diabetic patients contributes to elevated plasma glucose levels.

Glucagon and insulin each play major regulatory roles in glucose metabolism mediated by the liver. In response to a reduction in blood glucose, the alpha cells of the pancreas secrete glucagons, which in turn binds to its cell surface receptor on the liver. Glucagon receptor activation promotes protein kinase A-dependent phosphorylation of phosphorylase kinase. This, in turn, causes the phosphorylation of phosphorylase b;

PRD-2174

5

10

15

20

25

30

thereby converting glycogen phosphorylase to its active a form. Glycogen is converted to Glc-1-P and ultimately glucose to restore the plasma glucose to normal levels. When plasma glucose levels increase, insulin promotes glucose uptake in skeletal muscle and fat, and glycogen synthesis in the liver. In addition, phosphorylase-dependent glycogen breakdown is also blocked by insulin (Bollen, M., and Stalmans,) (1992) Crit. Rev. Biochem. Mol. Biol. 27:227-281). Therefore, the liver serves as an important buffer for the plasma glucose level and glycogen phosphorylase is positioned at a critical juncture for the reciprocal regulation of glucose metabolism.

Glycogen phosphorylase exists in two interconvertible forms: the dephosphorylated inactive form (phosphorylase b) and the phosphorylated active form (phosphorylase a) (reviewed by Newgard et al. (1989) Crit. Rev. Biochem. Mol. Biol. 24: 69-99). In resting muscle, glycogen phosphorylase is inactive (a form) and can be activated either by non-covalent cooperative binding of AMP or by covalent phosphorylation. Phosphorylase a does not require AMP for activation, althought addition of AMP can produce a 10-20% increase in activity (Oikonomakos et al., 1999) Protein Sci. 8: 1930-1945. Both forms can exist in a less active T-state and a more active R- state (Monod et al., (1965) (J. Mol. Biol. 12: 88-118). The T-state is stabilized by the binding of ATP, Glc-1-P, glucose and caffeine whereas the R-state is induced by AMP substrates and analogues (Johnson et al., (1989), In Allosteric enzymes. Boca Raton, FL: CRC Press, 81-127; Oikonomakos et al., 1992, and Johnson, L.N. (1992) FASEB J. 6: 2274-2282).

Caffeine has also been shown to regulate glycogen phosphorylase activity by binding to the purine inhibitory (I) site (Kasvinsky et al., (1978) J. Biol. Chem. 253: 3343-3351). Ercan-Fang et al., (1997) (J. Pharmacol. Exp. Ther. 280: 1312-1318). Although some glucose and purine nucleoside phosphorylase inhibitors reportedly inhibit glycogenolysis in rodent cells and tissues, none of these compounds maintain oral activity in vivo (Kasvinsky et al., (1981) Can. J. Biochem. 59: 387-395; Board, M. et al., (1995a) Eur. J. Biochem. 228: 753-761; Board, et al., (1995b) Biochem. J. 311: 845-852).

PRD-2174

5

10

15

20

Attempts to modulate hepatic glucose production (HGP) with gluconeogenesis inhibitors have yielded limited success. Agents that suppress gluconeogenesis *in vitro* or in diabetic rodents have not been clinically efficacious or safe in humans (Yki-Javinen, (1994) Diabetes Nutr. Metab. 7: 109-119; Bressler and Johnson, (1992) Diabetes Care 15: 792-805). These compounds inhibit gluconeogenesis by reducing gluconeogenic substrates or fatty acid metabolism (Bressler and Johnson, (1992). With the exception of Metformin, an antidiabetic agent with multiple effects including gluconeogenesis inhibition, most inhibitors have failed to reduce HGP and plasma glucose levels in humans caused by hepatic autoregulation, a compensatory increase in hepatic glycogenolysis that maintains a high rate of HGP (Yki-Javinen, 1994). The alternative approach to inhibit glycogenolysis to reduce HGP has not been thoroughly explored. The rate-limiting step of glucose production from the degradative phosphorolysis of glycogen to glucose-1-phosphate (Glc-1-P) is catalysed by glycogen phosphorylase (GP).

In short, glycogen phosphorylase has been implicated in the regulation of excessive hepatic glucose production - a significant contributor to diabetic hyperglycemia. Compounds which specifically inhibit glycogen phosphorylase should reduce blood glucose levels in the post-absorptive state; thereby providing adjunctive therapy for Type II (2) Diabetes. Administration of a selective agent which will specifically inhibit glycogen phosphorylase should result in reduced hepatic glucose production and increased deposition of glycogen in skeletal muscle with a concomitant reduction of blood glucose. The hypoglycemic effect of specific glycogen phosphorylase inhibitors would be advantageous for combination therapy.

PRD-2174

Summary of the Invention

The invention features pharmaceutically active quinoxalinones of formula (I), compositions containing them, and methods of making and using them.

5

10

Formula (I)

wherein R^1 is H, C ₁₋₆ alkyl, or halo;

R² is H or halo;

15 R^3 is H, C ₁₋₆ alkyl,

X is N or CH;

Y is a covalent bond, -NHCO- or -CONH-;

Z is phenyl or a 5 or 6-membered heterocyclyl with between 1 and 2 heteroatoms independently selected from N, O, and S; and

20 n is 0, 1 or 2;

or a pharmaceutically acceptable salt, ester, amide, hydrate, or solvate thereof.

The invention also features pharmaceutical compositions including one or more compounds of formula (I) and a pharmaceutically acceptable carrier or vehicle.

25

30

Another aspect of the invention is a method for treating a disease or condition mediated by glycogen phosphorylase, said method including administering to a patient in need of treatment an effective amount of a pharmaceutical composition which comprises a compound of formula (I). Such diseases or conditions include Type II diabetes and obesity.

PRD-2174

Other features and advantages of the invention will become apparent from the following disclosure and the appended claims.

Detailed Description

5

10

A. Terms

The following terms are defined below and by their usage throughout this disclosure.

"Alkyl" includes optionally substituted straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, isopentyl, secpentyl, hexyl, heptyl, octyl, and so on. Alkyl includes cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

15

20

25

30

"Alkoxy" includes an optionally substituted straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on. "Aminoalkyl", "thioalkyl", and "sulfonylalkyl" are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO₂. Heteroalkyl includes alkoxy, aminoalkyl, thioalkyl, and so on.

"Aryl" includes phenyl, naphthyl, biphenylyl, tetrahydronaphthyl, indenyl, and so on, any of which may be optionally substituted. Aryl also includes arylalkyl groups such as benzyl, phenethyl, and phenylpropyl. Aryl includes a ring system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system may be bicyclic, bridge, and/or fused. The system may include rings that are aromatic, or partially or completely saturated. Examples of ring systems include indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl, benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl, and so on.

PRD-2174

5

10

15

20

25

"Heterocyclyl" includes optionally substituted aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO₂, CO, CONH, COO) in the ring. Unless otherwise indicated, a heterocyclyl may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or 1-pyrazolyl. Preferably a monocyclic heterocyclyl has between 5 and 7 ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5 heteroatoms or heteroatom moieties in the ring, and preferably there are between 1 and 3, or between 1 and 2, or there may be 1 heteroatom or heteroatom moiety. A heterocyclyl may be saturated, unsaturated, aromatic (e.g., heteroaryl), nonaromatic, or fused.

"Heterocyclyl" also includes fused, e.g., bicyclic, rings, such as those optionally condensed with an optionally substituted carbocyclic or heterocyclic five- or six-membered aromatic ring. For example, "heteroaryl" includes an optionally substituted six-membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms condensed with an optionally substituted five- or six-membered carbocyclic or heterocyclic aromatic ring. Said heterocyclic five- or six-membered aromatic ring condensed with the said five- or six-membered aromatic ring may contain 1, 2 or 3 nitrogen atoms where it is a six-membered ring, or 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where it is a five-membered ring.

Examples of heterocyclyls include thiazoylyl, furyl, thienyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, and morpholinyl. For example, preferred heterocyclyls or heterocyclic radicals include morpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, thienyl, and more preferably, piperidinyl or morpholinyl.

PRD-2174

10

15

20

25

30

Examples illustrating heteroaryl are thienyl, furanyl, pyrrolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzothiazolyl.

5 "Acyl" refers to a carbonyl moiety attached to either a hydrogen atom (i.e., a formyl group) or to an optionally substituted alkyl or alkenyl chain, or heterocyclyl.

"Halo" or "halogen" includes fluoro, chloro, bromo, and iodo, and preferably fluoro or chloro as a substituent on an alkyl group, with one or more halo atoms, such as trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethoxy, or fluoromethylthio.

"Pharmaceutically acceptable salts, esters, and amides" or "salts, esters, amides, hydrates, and solvates" include carboxylate salts, amino acid addition salts, esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. These salts (or esters, and/or amides) may be, for example, C 1-8 alkyl, C₃₋₈ cycloalkyl, aryl, C₂₋₁₀ heteroaryl, or C₂₋₁₀ non-aromatic heterocyclic salts (or esters, and/or amides). Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate. These may include alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19, which is incorporated herein by reference. Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C 1-6 alkyl amines and secondary di (C 1-6 alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from

PRD-2174

ammonia, C ₁₋₃ alkyl primary amines, and di (C ₁₋₂ alkyl)amines. Representative pharmaceutically acceptable esters of the invention include C ₁₋₇ alkyl, C ₅₋₇ cycloalkyl, phenyl, and phenyl(C ₁₋₆)alkyl esters. Preferred esters include methyl and ethyl esters.

"Patient" or "subject" includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experiment, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient or subject is a human.

"Composition" includes a product comprising the specified ingredients in the specified amounts as well as any product that results from combinations of the specified ingredients in the specified amounts.

"Therapeutically effective amount" or "effective amount" means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the condition or disorder being treated.

Concerning the various radicals in this disclosure and in the claims, three general remarks are made. The first remark concerns valency. As with all hydrocarbon radicals, whether saturated, unsaturated or aromatic, and whether or not cyclic, straight chain, or branched, and also similarly with all heterocyclic radicals, each radical includes substituted radicals of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims. The context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or more hydrogen atoms removed (multivalent). An example of a bivalent radical linking two parts of the molecule is Y in formula (I) which links a phenyl to the $-(CH_2)_n$ -Z moiety.

8

10

15

20

PRD-2174

5

10

15

20

25

30

Second, alkyl and heterocyclyl groups as defined herein are understood to include substituted alkyl and heterocyclyl groups. Hydrocarbyls include monovalent radicals containing carbon and hydrogen such as alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl (whether aromatic or unsaturated), as well as corresponding divalent (or multi-valent) radicals such as alkylene, alkenylene, phenylene, and so on. Heterocarbyls include monovalent and divalent (or multi-valent) radicals containing carbon, optionally hydrogen, and at least one heteroatom. Examples of monovalent heterocarbyls include acyl, acyloxy, alkoxyacyl, heterocyclyl, heteroaryl, aroyl, benzoyl, dialkylamino, hydroxyalkyl, and so on. Using "alkyl" as an example, "alkyl" should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents. Preferably, an alkyl group has between 1 and 3 substituents. The substituents may be the same (dihydroxy- or dimethyl-substituted), similar (chlorofluoro-substituted), or different (chloro- or aminomethyl-substituted). Examples of substituted alkyl include haloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, trifluoromethyl, and 3-iodocyclopentyl), hydroxyalkyl (such as hydroxymethyl, hydroxyethyl, 2-hydroxypropyl), aminoalkyl (such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and 2-aminopropyl), nitroalkyl, alkylalkyl, and so on. A di(C 1-6 alkyl)amino group includes independently selected alkyl groups, to form, for example, methylpropylamino and isopropylmethylamino, in addition dialkylamino groups having two of the same alkyl group such as dimethyl amino or diethylamino. Similarly, "heterocyclyl" is understood to be substituted

Third, only stable compounds are intended.

Compounds of the invention are further described in the next section.

B. Compounds

The invention features compounds of formula (I). Examples of such compounds include those compounds of formula (I) wherein: (a) R^1 is H; (b) R^2 is H; (c) R^3 is H or C ₁₋₃ alkyl; (d) n is 0 or 1; (e) Y is -CONH-; (f) R^3 is an alkyl substituted with hydroxy, carboxy, dimethylamino, piperidinyl, pyridyl, or morpholinyl; (g) Z is selected from

PRD-2174

5

25

30

phenyl, furanyl, thiophenyl, isoxazolyl, pyridazyl, pyrazolyl, N-methyl-pyrazolyl, pyrimidyl, pyrrolyl, N-methyl-pyrrole, imidazolyl, pyridyl, oxazolyl, and thiazolyl; (h) Z is selected from furanyl, thiophenyl, isoxazolyl, and pyrazolyl; (i) R¹ is H; R² is H; and R³ is H or C ₁₋₂ alkyl; (j) n is 0 or 1; and Y is –CONH-; (k) Z is selected from furanyl, thiophenyl, isoxazolyl, pyridazyl, pyrazolyl, pyrimidyl, pyrrolyl, imidazolyl, pyridyl, oxazolyl, and thiazolyl; (l) limitations of (k) and n is 0 or 1; (m) limitations of (i) and (j); (n) limitations of (g), (i), and (j); (o) limitations of (e) and (i); and combinations of the above.

Examples of preferred compounds where Y=CONH include:

N-Isoxazol-3-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide;

N-Isoxazol-5-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)benzamide;

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-furan-2-ylmethylbenzamide;

N-Isoxazol-3-yl-4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-

20 benzamide;

4-(7-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide; and

4-(4-Methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-N-thiophen-2-ylmethyl-benzamide.

4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethylbenzamide;

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1*H*-pyrazol-3-yl)-benzamide;

N-Isoxazol-3-yl-4-[4-(2-Morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino]-benzamide;

PRD-2174

5

0

5

0

4-(4,6-Dimethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide;

4-[4-(2-hydroxy-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide;

N-Isoxazol-3-yl-4-(4-Methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-benzamide;

4-[4-(2-morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide; and

4-[4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide.

Examples of preferred compounds where Y=NHCO include:

Isoxazole-5-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide;

Isoxazole-3-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide; and N- [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-

More preferred compounds where Y is a covalent bond include:

1-Methyl-3-[4-(1H-pyrrol-2-yl)-phenylamino]-1*H*-quinoxalin-2-one; and 3-(4-imidazol-1-yl-phenylamino)-1-methyl-1*H*-quinoxalin-2-one.

5 Additional preferred compounds include:

nicotinamide.

N-Isoxazol-3-yl-4-(7-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;

4-(6-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide;

N-Isoxazol-3-yl-4-(6-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;

PRD-2174

N-Isoxazol-3-yl-4-(6-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide; N-Isoxazol-3-yl-4-(7-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide; 5 4-(6-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2- ylmethyl-benzamide; 4-(7-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2- ylmethyl-benzamide; N-Isoxazol-3-yl-4-[4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-10 2ylamino]-benzamide; 4-(4-Ethyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-N-thiophen-2ylmethyl-benzamide; N-Isoxazol-3-yl-4-(4-ethyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2ylamino)- benzamide; N-Isoxazol-3-yl-4-[7-fluoro-4-(2-Morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-15 quinoxalin-2ylamino]-benzamide; 4-[7-Fluoro-4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide; 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-oxazol-2-yl-20 benzamide; N-Furan-2-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)benzamide; 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylbenzamide; 25 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1*H*-pyrrol-3-yl)benzamide; 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1-methyl-1Hpyrrol-3-yl)-benzamide; 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(pyrimidin-2-yl)-30 benzamide;

PRD-2174

5

N-(1*H*-Imidazol-2-yl)-4-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;

4-[4-(2-pyrrolidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide; and

N-Isoxazol-3-ylmethyl-4-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide.

PRD-2174

5

C. Synthesis

The compounds of the invention can be made according to both conventional synthetic organic methods, as well as combinatorial or matrix synthetic methods. The following three schemes and remarks are exemplified in Examples 1-78.

General Synthetic Scheme for Quinoxalinones where Y=CONH

10 Synthesis of analogues where Y=CONH begins with either alkylation of the appropriately substituted 2-nitro-aniline or addition of a substituted amine to the appropriately substituted 2-fluoro-nitrobenzene. The nitro group is reduced to the amine, and the diamine is treated with diethyl oxalate to give the quinoxalindione. Reaction of the dione with phosphorous oxychloride gives the chloroimidate. Addition of methyl 4-amino-benzoate to the chloroimidate followed by amide formation with the appropriate amine gives the desired compounds.

PRD-2174

SCHEME 1

PRD-2174

General Synthetic Scheme for Quinoxalinones where Y= NHCO

The chloroimidate for analogues where Y=NHCO is synthesized in a manner similar to that which was described earlier. Addition of 1,4-diamino-benzene to the chloroimidate followed by reaction with the appropriate acid chloride gives the desired compounds, as shown in Scheme 2.

10

5

SCHEME 2

15

General Synthetic Scheme for Quinoxalinones where Y= Covalent Bond

The chloroimidate for analogues where Y=NHCO is synthesized in a manner similar to that which was described earlier. Addition of 4-iodo-aniline followed by palladium catalyzed coupling with the appropriate boronic acid or stannane gives the desired compound. Alternatively, the appropriately 4-substituted aniline can be added to the chloroimidate to give the desired compound in a single operation. (Scheme 3)

PRD-2174

SCHEME 3

$$\begin{array}{c} R_1 \\ R_2 \\ \end{array} \begin{array}{c} R_3 \\ \end{array} \begin{array}{c} R_3 \\ \end{array} \begin{array}{c} A\text{-I-aniline} \\ \end{array} \begin{array}{c} R_1 \\ \end{array} \begin{array}{c} R_3 \\ \end{array}$$

5

10

PRD-2174

5

10

15

20

25

30

D. Formulation and Administration

The compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. To prepare these pharmaceutical compositions, an effective amount of a particular compound, for example, in base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.

A carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for oral administration or parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. These include water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. In view of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are generally employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Such additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition

PRD-2174

5

10

15

20

25

30

salts of the compounds of formula I, due to their increased water solubility over the corresponding base form, are more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

Pharmaceutically acceptable acid addition salts include the therapeutically active non-toxic acid addition salt forms, which the disclosed compounds are able to form. The latter can conveniently be obtained by treating the base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, palmoic and the like acids. The term addition salt also comprises the solvates which the disclosed componds, as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like. Conversely the salt form can be converted by treatment with alkali into the free base form.

Stereoisomeric forms define all the possible isomeric forms that the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the (R)- or (S)-configuration;

PRD-2174

5

10

15

20

25

30

substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration. The invention encompasses stereochemically isomeric forms including diastereoisomers, as well as mixtures thereof in any proportion of the disclosed compounds. The disclosed compounds may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above and following formulae are intended to be included within the scope of the present invention

Those of skill in the treatment of disorders or conditions mediated by glycogen phosphorylase could easily determine the effective daily amount from the test results presented hereinafter and other information. In general it is contemplated that a therapeutically effective dose would be from 0.001 mg/kg to 5 mg/kg body weight, more preferably from 0.01 mg/kg to 0.5 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 250 mg or 750 mg, and in particular 0.5 to 50 mg of active ingredient per unit dosage forms. Examples include 2 mg, 4 mg, 7 mg, 10 mg, 15 mg, 25 mg, and 35 mg dosage forms. Compounds of the invention may also be prepared in time-release or subcutaneous or transdermal patch formulations. Disclosed compound may also be formulated as a spray or other topical or inhalable formulations.

The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines.

The next section includes detailed information relating to the use of the disclosed compounds and compositions.

PRD-2174

E. Uses

The compounds and compositions of the invention are pharmaceutically active. For example, they may be used to treat glycogen phosphorylase-mediated conditions and diseases. These disease include NIDDM or Type II (2) Diabetes, hyperglycemia (particularly in a post-absorptive state).

PRD-2174

F. Examples

5

Compound 1:

1-Methyl-1,4-dihydro-quinoxaline-2,3-dione

Method A:

To a solution of N-methyl-1,2-phenylenediamine (5g, 41 mmol) in dichloromethane (80 mL) at 0° C was added triethylamine (11.4 mL, 82 mmol) followed by dropwise addition ethyl chlorooxoacetate (4.6 mL, 41 mmol). The mixture was stirred at room temperature for 2h, then at 60°C for 2h. The mixture was cooled and the precipitate that formed was collected by vacuum filtration, washed with hexanes and dried to give a light pink solid.

15

20

10

Compound 2:

3-Chloro-1-methyl-1H-quinoxalin-2-one

Method B:

To a suspension of compound 1 (3g, 17 mmol) in toluene (30 mL) was added disopropylethyl amine (2.4 mL, 13.6 mmol) followed by phosphorous oxychloride (2.4 mL, 25.6 mmol). The mixture was stirred at 110°C for 3h. The solvent was removed *in vacuo*, and the resulting dark residue was dissolved in dichloromethane, washed with

PRD-2174

5

10 -

cold saturated sodium bicarbonate solution, dried (magnesium sulfate), and passed thru a short column of silica gel. The solution was concentrated *in vacuo* to give a white solid.

Compound 3:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzoic acid methyl ester

Method C:

To a solution of compound 2 (1.4 g, 7.3 mmol) in acetonitrile (20 mL) was added methyl 4-aminobenzoate (1 g, 6.6 mmol). The reaction was stirred at 80°C overnight. The precipitated solid was collected by vacuum filtration, washed with saturated sodium bicarbonate solution and water, and dried *in vacuo* to give a white solid.

Compound 4:

N-Isoxazol-3-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide

15

20

Method D:

To a solution of trimethylaluminum (2M in hexanes, 0.62 mmol, 0.31 mL) in toluene (1.5 mL) at room temperature was added 3-aminoisoxazole (0.31 mmol, 26 mg) in toluene (0.5 mL) dropwise via syringe. After 30 min, compound 3 was added and the reaction was heated to reflux for 5h. The mixture was cooled, quenched with 1N hydrochloric acid solution, and the mixture is extracted with ethyl acetate. The combined organic layers are

PRD-2174

washed with brine and dried (magnesium sulfate). After removal of solvent *in vacuo* purification of the resulting solid on silica gel (15% ethyl acetate/ dichloromethane) gave a white solid. ¹H NMR (DMSO) δ 11.29 (s, 1H), 9.81 (s, 1H), 8.85 (d, J=1.3 Hz, 1H), 8.34 (d, J=8.7 Hz, 2H), 8.06 (d, J=8.9 Hz, 2H), 7.64 (d, J=7.6 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.43-7.31 (m, 2H), 7.07 (d, J=1.3 Hz, 1H), 3.72 (s, 3H).

Compound 5:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1H-pyrazol-3-yl)-benzamide

10

15

5

Compound 5 was obtained as a yellow solid from 3-aminopyrazole and compound 3 by method D. 1 H NMR (DMSO) δ 12.41 (s, 1H), 10.65 (s, 1H), 9.74 (s, 1H), 8.30 (d, J=8.6 Hz, 2H), 8.03 (d, J=8.6 Hz, 2H), 7.63 (m, 1H), 7.50 (m, 1H), 7.43-7.30 (m, 2H), 6.65 (bs, 1H), 3.72, (s, 3H).

Compound 6:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiazol-2-yl-benzamide

PRD-2174

Compound 6 was obtained as a yellow solid from 3-aminothiazole and compound 3 by method D. 1 H NMR (DMSO) δ 12.48 (s, 1H), 9.84 (s, 1H), 8.35 (d, J=8.8 Hz, 2H), 8.13 (d, J=8.8 Hz, 2H), 7.65 (dd, J=7.7, 1.6 Hz, 1H), 7.56 (d, J=3.6 Hz, 1H), 7.51 (m, 1H), 7.44-7.31 (m, 2H), 7.27 (d, J=3.4 Hz, 1H), 3.72 (s, 3H).

5

Compound 7:

N-Isoxazol-5-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide

10

15

Compound 7 was obtained as a yellow solid from 5-aminoisoxazole and compound 3 by method D. 1 H NMR (DMSO) δ 11.89 (s, 1H), 9.84 (s, 1H), 8.51 (d, J=1.8 Hz, 1H), 8.36 (d, J=8.8 Hz, 2H), 8.06 (d, J=8.9 Hz, 2H), 7.64 (dd, J=7.6, 1.2 Hz, 1H), 7.51 (d, J=7.9 Hz, 1H), 7.43-7.31 (m, 2H), 6.43 (d, J=1.9 Hz, 1H), 3.72 (s, 3H).

Compound 8:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1H-pyrazol-3-yl)-benzamide

PRD-2174

Compound 8 was obtained as a white solid from 3-amino-1-methylpyrazole and compound 3 by method D. 1 H NMR (DMSO) δ 10.66 (s, 1H), 9.74 (s, 1H), 8.28 (d, J=8.7 Hz, 2H), 8.02 (d, J=8.8 Hz, 2H), 7.62 (m, 2H), 7.50 (m, 1H), 7.42-7.31 (m, 2H), 6.60 (d, J=2.3 Hz, 1H), 3.79 (s, 3H), 3.72 s, 3H)

5

Compound 9:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-3-yl-benzamide

10

15

Compound 9 was obtained from 3-aminothiophene and compound 3 by method D as a yellow solid (37 mg). ¹H NMR (DMSO) δ 10.53 (s, 1H), 9.74 (s, 1H), 8.30 (d, J=9.0 Hz, 2H), 7.97 (d, J=9.0 Hz, 2H), 7.71 (dd, J=3.2, 1,2 Hz, 1H), 7.60 (dd, J= 7.7, 1.6 Hz, 1H), 7.49-7.30 (m, 5H), 3.7 (s, 3H).

Compound 10:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide

20

Compound 10 was obtained as a white solid from 2-aminomethyl-thiophene and compound 3 by method D. 1 H NMR (DMSO) δ 9.70 (s, 1H), 9.01 (t, J=5.7 Hz, 1H), 8.26

PRD-2174

(d, J=8.7 Hz, 2H), 7.89 (d, J=8.77 Hz, 2H), 7.61 (dd, J=7.7, 1.5 Hz, 1H), 7.49 (dd, J=8.2, 1.3 Hz, 1H), 7.41-7.29 (m, 3H), 7.03, (m, 1H), 6.97 (dd, J=5.0, 3.4 Hz, 1H), 4.64 (d, J=5.8 Hz, 2H), 3.71 (s, 3H).

5

Compound 11:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-furan-2-ylmethyl-benzamide

Compound 11 was obtained as a white solid from 2-aminomethyl-furan and compound 3 by method D. ¹H NMR (DMSO) δ 9.69 (s, 1H), 8.84 (t, J=6.2 Hz, 1H), 8.26 (d, J=8.7 Hz, 2H), 7.89 (d, J=8.7 Hz, 2H), 7.60 (m, 1H), 7.49 (dd, J=8.2, 1.2 Hz, 1H), 7.41-7.29 (m, 2H), 6.40, (dd, J=3.2, 1.9 Hz, 1H), 6.28 (dd, J=3.2, 0.7 Hz, 1H), 4.47 (d, J=5.6 Hz, 2H), 3.71 (s, 3H).

15

Compound 12:

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-pyrazin-2-yl-benzamide

PRD-2174

Compound 12 was obtained as a white solid from aminopyrazine and compound 3 by method D. ¹H NMR (DMSO) δ 11.69 (s, 1H), 10.97 (s, 1H), 9.82 (s, 1H), 9.44 (d, J=1.6 Hz, 1H), 8.48 (m, 1H), 8.41 (d, J=2.5 Hz, 1H), 8.34 (d, J=8.8 Hz, 2H), 8.09 (d, J=8.8 Hz, 2H), 7.64 (dd, J=7.7, 1.7 Hz, 1H), 7.51 (dd, J=8.2, 1.2 Hz, 1H), 7.43-7.31 (m, 2H), 3.72 (s, 3H).

Compound 13:

3-(4-amino-phenylamino)-1-methyl-1*H*-quinoxalin-2-one

10

5

Compound 13 was obtained as a white solid from 1,4-diaminobenzene and compound 2 by method C.

Compound 14:

Isoxazole-5-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide

PRD-2174

Method E:

To a suspension of compound 13 (50 mg, 0.19 mmol) in dichloromethane (2 mL) at room temperature was added pyridine (23 μ L, 0.28 mmol) followed by isoxazole-5-carbonyl chloride (25 mg, 0.19 mmol). After 30 min, the precipitated solid was collected by vacuum filtration, washed with water and dichloromethane, and dried *in vacuo* to give compound 14 as a white solid. ¹H NMR (DMSO) δ 10.73 (s, 1H), 9.52 (s, 1H) 8.82 (d, J=1.9 Hz, 1H), 8.17 (d, J= 9 Hz, 2H), 7.75 (d, J=9 Hz, 2H), 7.59 (dd, J=7.6, 1.5 Hz, 1H), 7.47 (m, 1H), 7.38-7.27 (m, 2H), 7.25 (d, J=1.7 Hz, 1H), 3.71 (s, 3H).

10

5

Compound 15:

Isoxazole-3-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide

Compound 15 was obtained as a white solid from compound 13 and isoxazole-3-carbonyl chloride by method E. ¹H NMR (DMSO) δ 10.69 (s, 1H), 9.50 (s, 1H) 9.16 (d, J=1.7 Hz, 1H), 8.16 (d, J= 9.1 Hz, 2H), 7.77 (d, J=9.1 Hz, 2H), 7.59 (dd, J=8.7, 1.7 Hz, 1H), 7.46 (dd, J= 8.2, 1.4 Hz, 1H), 7.38-7.27 (m, 2H), 7.03 (d, J=1.7 Hz, 1H), 3.71 (s, 3H).

20

Compound 16:

N- [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-nicotinamide

PRD-2174

Compound 16 was obtained as a white solid from compound 13 and nicotinoyl chloride by method E. 1 H NMR (DMSO) δ 10.66 (s, 1H), 9.54 (s, 1H), 9.27 (d, J=1.3 Hz, 1H), 8.89 (dd, J=5.1, 1.5 Hz, 1H), 8.61 (m, 1H), 8.17 (d, J=8.9 Hz, 2H), 7.83 (m, 1H), 7.79 (d, J=8.9 Hz, 2H), 7.59 (dd, J=7.3, 1.9 Hz, 1H), 7.47 (m, 1H), 7.38-7.27 (m, 2H), 3.71 (s, 3H)

Compound 17:

Thiophene-2-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide

Compound 17 was obtained as a white solid from compound 13 and thiophene-2-carbonyl chloride by method E. ¹H NMR (DMSO) δ 10.21 (s, 1 H), 9.47 (s, 1H), 8.14 (d, J=9 Hz, 2H), 8.02 (dd, J=3.8, 1.1 Hz, 1H), 7.85 (dd, J=5.1, 1.0 Hz, 1H), 7.70 (d, J= 9 Hz, 2H), 7.58 (dd, J=7.4, 1.8 Hz, 1H), 7.46 (dd, J=8.2, 1.5 Hz, 1H), 7.37-7.26 (m, 2H), 7.23 (dd, J=4.9, 3.8 Hz, 1H), 3.71 (s, 3H).

15

PRD-2174

Compound 18:

Furan-2-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide

5

10

15

20

Compound 18 was obtained as a white solid from compound 13 and furan-2-carbonyl chloride by method E. 1 H NMR (DMSO) δ 10.16 (s, 1 H), 9.46 (s, 1H), 8.12 (d, J=9.1 Hz, 1H), 7.94 (dd, J=1.7, 0.8 Hz, 1H), 7.73 (d, J= 9 Hz, 2H), 7.58 (dd, J=7.5, 1.6 Hz, 1H), 7.46 (dd, J=8.0, 1.5 Hz, 1H), 7.37-7.26 (m, 3H), 6.71 (dd, J=3.4, 1.7Hz, 1H), 3.71 (s, 3H).

Compound 19:

1-Methyl-1*H*-pyrrole-2-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide

Compound 19 was obtained as a white solid from compound 13 and 1-methylpyrrole-2-carbonyl chloride by method E. ¹H NMR (CDCl₃) δ 8.43 (s, 1H), 7.96 (d, J=9.1 Hz, 2H), 7.68 (m, 1H), 7.59 (d, J=9.1 Hz, 2H0, 7.33-7.24 (m, 3H), 6.79 (m, 1H), 6.71 (m, 1H), 6.16 (m, 1H), 4.00 (s, 3H), 3.78 (s, 3H).

PRD-2174

Compound 20:


3-(4-iodo-phenylamino)-1-methyl-1H-quinoxalin-2-one

Compound 20 was obtained as a yellow solid from compound 2 and 4-iodo-aniline by method C.

5

Compound 21:

3-(4-furan-3-yl-phenylamino)-1-methyl-1*H*-quinoxalin-2-one



10 To a degassed solution of compound 20 (100 mg, 0.27 mmol), furan-3-boronic acid (45

mg, 0.4 mmol), and tetrakis(triphenylphosphine) palladium (31 mg, 0.027 mmol) in dimethoxyethane (1.5 mL) at room temperature was added aqueous 2N sodium carbonate solution (1.5 mL). The reaction was stirred under an atmosphere of nitrogen overnight at 95°C. The mixture was cooled and diluted with ethyl acetate. The mixture was washed with saturated sodium bicarbonate solution, water, and brine, dried over sodium sulfate, and concentrated in vacuo. After purification on silica gel (50% hexane/ dichloromethane), compound 21 was obtained as a yellow solid. ¹H NMR (CDCl₃) δ 8.49 (s, 1H), 7.99 (d, J=8.7 Hz, 2H), 7.73 (m, 2H), 7.52 (d, J=8.7 Hz, 2H), 7.49 (m, 1H), 7.36-7.24 (m, 3H), 6.72 (s, 1H), 3.76 (s, 3H).

20

15

Compound 22:

1-Methyl-3-[4-(1H-pyrrol-2-yl)-phenylamino]-1*H*-quinoxalin-2-one

PRD-2174

To degassed solution of compound 20 (50 0.13 mmol). 1-(tmg, butoxycarbonyl)pyrrole-2-boronic acid (42 mg, 0.2 mmol), and tetrakis(triphenylphosphine) palladium (16 mg, 0.013 mmol) in dimethoxyethane (1 mL) at room temperature was added aqueous 2N sodium carbonate solution (1 mL). The reaction was stirred under an atmosphere of nitrogen overnight at 95°C. The mixture was cooled and diluted with ethyl acetate. The mixture was washed with saturated sodium bicarbonate solution, water, and brine, dried over sodium sulfate, and concentrated in vacuo. After purification on silica gel (50% hexane/ dichloromethane), the resulting yellow solid is heated at 185°C for 20 min. The residue was purified on silica gel (10% ethyl acetate/ dichloromethane) to give compound 22 as a yellow solid. 1H NMR (CDCl₃) δ 8.48 (s, 1H), 8.43 (bs, 1H), 7.99 (d, J=8.8 Hz, 2H), 7.70 (m, 1H), 7.51 (d, J=8.8 Hz, 2H), 7.51 (d, J=8.6 Hz, 1H), 7.36-7.24 (m, 3H), 6.87 (m, 1H), 6.65 (m, 1H), 6.31 (m, 1H), 3.78 (s, 3H).

Compound 23:

3-(4-imidazol-1-yl-phenylamino)-1-methyl-1*H*-quinoxalin-2-one

20

5

10

PRD-2174

Compound 23 was obtained as a yellow solid from compound 2 and 4-(1*H*-imidazol-1-yl) aniline by method C. 1 H NMR (CDCl₃) δ 8.55 (s, 1H), 8.10 (d, J=8.9 Hz, 2H), 7.85 (bs (1H), 7.73-7.70 (m, 1H), 7.42 (d, J=8.9 Hz, 2H), 7.38-7.26 (m, 4H), 7.22 (bs, 1H), 3.80 (s, 3H).

Compound 24:

N-ethyl-1,2-phenylenediamine

10 Method F:

5

To a solution of 1-ethyl-2-nitro-aniline (2g, 12.1 mmol) in ethanol (40 mL) was added 10% palladium on carbon (500 mg). The mixture was reacted in a Paar apparatus under 50 psi of hydrogen gas for 2h. The mixture was filtered thru celite, the celite was washed with ethyl acetate, and the combined organic solvents were concentrated *in vacuo*.

15 Compound 24 was obtained as a yellow oil.

Compound 25:

1-Ethyl-1,4-dihydro-quinoxaline-2,3-dione

20 Compound 25 was obtained as a white solid from compound 24 by method A.

PRD-2174

Compound 26:

3-Chloro-1-ethyl-1H-quinoxalin-2-one

5

Compound 26 was obtained as a gray solid from compound 25 by method B.

Compound 27:

4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzoic acid methyl ester

10

Compound 27 was obtained as a white solid from compound 26 and methyl 4-aminobenzoate by method C.

15

Compound 28:

N-Isoxazol-3-yl-4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide

PRD-2174

Compound 28 was obtained as a yellow solid from compound 27 by method D. ¹H NMR (DMSO) δ 11.29 (s, 1H), 9.80 (s, 1H), 8.85 (d, J=1.7 Hz, 1H), 8.33 (d, J=9.0 Hz, 2H), 8.06 (d, J=8.9 Hz, 2H), 7.66-7.30 (m, 4H), 7.07 (d, J=1.7 Hz, 1H), 4.36 (q, J=7.1 Hz, 2H), 1.30 (t, J=7.1 Hz, 3H).

Compound 29:

4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1*H*-pyrazol-3-yl)-benzamide

10

5

Compound 29 was obtained as a yellow solid from compound 27 by method D. 1H NMR (DMSO) δ 12.4 (s, 1H), 10.64 (s, 1H), 9.73 (s, 1H), 8.28 (d, J=8.9 Hz, 2H), 8.03 (d, J=8.9 Hz, 2H), 7.60 (m, 2H), 7.56 (m, 1H), 7.42-7.29 (m, 2H), 6.65 (s,1H), 4.36 (q, J=7.1 Hz, 2H), 1.30 (t, J=7.1 Hz, 3H).

Compound 30:

4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiazol-2-yl-benzamide

20

PRD-2174

5

Compound 30 was obtained as a white solid from compound 27 by method D. ^{1}H NMR (DMSO) δ 12.47 (s, 1H), 9.82 (s, 1H), 8.34 (d, J=8.8 Hz, 2H), 8.12 (d, J=8.8 Hz, 2H), 7.66 (dd, J= 7.7, 1.5 Hz, 1H), 7.56 (m, 2H), 7.44-7.30 (m, 2H), 7.27 (d, J=3.4 Hz, 1H), 4.36 (q, J=6.9 Hz, 2H), 1.31 (t, J=6.9 Hz, 3H).

Compound 31:

4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide

Compound 31 was obtained as a white solid from compound 27 by method D. ¹H NMR (DMSO) δ 9.69 (s, 1H), 9.02 (t, J=6.0 Hz, 1H), 8.25 (d, J=8.9 Hz, 2H), 7.89 (d, J=8.9 Hz, 2H), 7.62 (dd, J= 7.7, 1.5 Hz, 1H), 7.55 (m, 1H), 7.41-7.28 (m, 3H), 7.03, (dd, J=3.4, 1.0 Hz, 1H), 6.96 (dd, J=5.1, 3.4 Hz, 1H), 4.64 (d, J=5.8 Hz, 2H), 4.35 (q, J=6.9 Hz, 2H), 1,29 (t, J=6.9 Hz, 3H).

Compound 32:

N²-Methyl-pyridine-2,3-diamine

20

15

Compound 32 was obtained as an oil from 2-methylamino-3-nitro-pyridine by method F.

PRD-2174

Compound 33:

4-Methyl-1,4-dihydro-pyrido[2,3-b]pyrazine-2,3-dione

5

Compound 33 was obtained as a white solid from compound 32 by method A.

Compound 34:

10

2-Chloro-4-methyl-4*H*-pyrido[2,3-*b*]pyrazine-3-one

Compound 34 was obtained as a white solid from compound 33 by method B.

15

Compound 35:

4-(4-Methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-N-thiophen-2-ylmethyl-benzamide

PRD-2174

5

15

Compound 35 was obtained as a yellow solid from compound 34 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. ¹H NMR (DMSO) δ 9.86 (s, 1H), 9.04 (t, J=5.6 Hz, 1H), 8.38 (m, 1H), 8.27 (d, J=8.8 Hz, 2H), 7.99 (m, 1H), 7.90 (d, J=8.8 Hz, 2H), 7.39-7.34 (m, 1H), 7.02 (m, 1H), 6.96 (m, 1H), 4.64 (d, J=5.7 Hz, 2H), 3.75 (s, 3H).

Compound 36:

N-Isoxazol-3-yl-4-(4-Methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-

10 benzamide

Compound 36 was obtained as a yellow solid from compound 34 and 4-amino-N-isoxazol-3yl-benzamide by method C. ¹H NMR (DMSO) δ 11.31 (s, 1H), 9.96 (s, 1H), 8.85 (d, J=1.7 Hz, 1H), 8.40 (dd, J=4.7, 1.7 Hz, 1H), 8.34 (d, J=8.9 Hz, 2H), 8.06 (d, J=8.9 Hz, 2H), 8.02 (dd, J=7.8, 1.6 Hz, 1H), 7.38 (dd, J=7.8, 4.8 Hz, 1H), 7.07 (d, J=1.7 Hz, 1H), 3.76 (s, 3H).

Compound 37:

Methyl-(5-methyl-2-nitro-phenyl)-amine

WO 2005/067932

PCT/US2004/043409

PRD-2174

Method G:

To a suspension of sodium hydride (95%, 684 mg, 27.1 mmol) in DMF (50 mL) at 0°C was added a solution of 5-methyl-2-nitro-aniline (4g, 26.3 mmol) in DMF (40mL). After stirring for 10 minutes, methyl iodide (7.2 mL, 114.8 mmol) was added dropwise over 20 min. The reaction was stirred for 1h at 0°C and then at room temperature for 1h. The reaction was diluted with water, stirred for 10 min, and compound 37 was obtained as a red solid and collected by vacuum filtration.

10

5

Compound 38:

4, N²-Dimethyl-benzene-1,2-diamine

Compound 38 was obtained as an oil from compound 37 by method F.

15

Compound 39:

1,7-Dimethyl-1,4-dihydro-quinoxaline-2,3-dione

Compound 39 was obtained as a gray solid from compound 38 by method A.

PRD-2174

Compound 40:

3-Chloro-1,7-dimethyl-1*H*-quinoxalin-2-one

5

Compound 40 was obtained as a brown solid from compound 39 by method B.

Compound 41:

4-(4,6-Dimethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-1-2-

10

benzamide

Compound 41 was obtained as a white solid from compound 40 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. 1 H NMR (DMSO) δ 9.63 (s, 1H), 9.03 (t, J=5.8 Hz, 1H), 8.25 (d, J=8.9 Hz, 2H), 7.89 (d, J=8.9 Hz, 2H), 7.52 (d, J=8.1 Hz, 1H), 7.39 (dd, J=5.21, 1.4 Hz, 1H), 7.33 (s, 1H), 7.16 (dd, J= 8, 1 Hz, 1H), 7.03 (d, J=3.5 Hz, 1H), 6.98 (dd, J= 5.2, 3.5 Hz, 1H), 4.64 (d, J=5.8 Hz, 2H), 3.71 (s, 3H), 2.46 (s, 3H).

Compound 42:

20

15

(4-Fluoro-2-nitro-phenyl)-methyl-amine

PRD-2174

10

15

Compound 42 was obtained as a red solid from 4-fluoro-2-nitro-aniline by method G.

Compound 43:

5 4-Fluoro-N¹-methyl-benzene-1,2-diamine

Compound 43 was obtained as an oil from compound 42 by method F.

Compound 44:

6-Fluoro-1-methyl-1,4-dihydro-quinoxaline-2,3-dione

Compound 44 was obtained as a gray solid from compound 43 by method A.

Compound 45:

3-Chloro-6-fluoro-1-methyl-1*H*-quinoxalin-2-one

PRD-2174

5

Compound 45 was obtained as a brown solid from compound 44 by method B.

Compound 46:

4-(7-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethylbenzamide

10 Compound 46 was obtained as a white solid from compound 45 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. ¹H NMR (DMSO) δ 9.82 (s, 1H), 9.05 (t, J=5.7 Hz, 1H), 8.25 (d, J=8.8 Hz, 2H), 7.89 (d, J=8.8 Hz, 2H), 7.51 (m, 1H), 7.43-7.38 (m, 2H), 7.25 (m, 1H), 7.02 (m, 1H), 7.67 (m, 1H), 4.64 (d, J=5.9 Hz, 2H), 3.70 (s, 3H).

15 Compound 47:

[2-(tert-Butyl-dimethyl-silanoxy)-ethyl]-(2-nitro-phenyl)-amine

PRD-2174

5

Compound 47 was obtained from 2-nitro-aniline and 2-bromoethoxy *tert*-butyl-dimethylsilane by method G.

Compound 48:

N-[(2-tert-butyl-dimethyl-silanyloxy)-ethyl]-benzene-1,2-diamine

Compound 48 was obtained as a dark solid from compound 47 by method F.

10 Compound 49:

1-[(2-tert-butyl-dimethyl-silanyloxy)-ethyl]-1,4-dihydro-quinoxaline-2,3-dione

15

Compound 49 was obtained as a gray solid from compound 48 by method A.

Compound 50:

3-Chloro-1-(2-hydroxy-ethyl)-1*H*-quinoxalin-2-one

WO 2005/067932

PCT/US2004/043409


PRD-2174

Compound 50 was obtained as a dark solid from compound 49 by method B.

5

Compound 51:

4-[4-(2-hydroxy-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide



Compound 51 was obtained as a white solid from compound 50 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. ¹H NMR (DMSO) δ 9.69 (s, 1H), 9.02 (t, J=5.7 Hz, 1H), 8.26 (d, J=8.9 Hz, 2H), 7.88 (d, J=8.9 Hz, 2H), 7.62-7.57 (m, 2H), 7.40-7.27 (m, 3H), 7.03 (dd, J=3.5, 1 Hz, 1H), 6.97 (dd, J= 5.1, 3.5 Hz, 1H), 4.92 (t, J=5.9 Hz, 1H), 4.64 (d, J= 5.7 Hz, 2H), 4.40 (t, J=6.1 Hz, 2H), 3.75 (appq, J=6.1 Hz, 2H)

15

Compound 52:

(2-Morpholin-4-yl-ethyl)-(2-nitro-phenyl)-amine

PRD-2174

Method H:

5

10

To a mixture of 2-fluoronitrobenzene (6.3 mL, 59.3 mmol) and sodium acetate (138 mg, 1.68 mmol) at room temperature was added 4-(aminoethyl)-morpholine (7.4 mL, 56.1 mmol) dropwise. The reaction was stirred at 80°C for 1h. The reaction was cooled to room temperature, added to water, and extracted with ethyl acetate (2x). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated *in vacuo*. After column chromatography on silica (5%-15% methanol in dichloromethane), compound 52 was obtained as an orange oil.

Compound 53:

1-(2-Morpholin-4-yl-ethyl)-1,4-dihydro-quinoxaline-2,3-dione

15 Method I:

To a solution of compound 52 (8.1 g, 32.3 mmol) in ethanol (55 mL) was added palladium on carbon (10%, 750 mg). The mixture was reacted in a Paar apparatus under 50psi of hydrogen for 2h. The mixture was filtered through Celite, the Celite pad was washed with ethanol, and the solution was concentrated *in vacuo* until the total volume


PRD-2174

was approximately 50 mL. To this solution was added diethyl oxalate (20 mL) and the mixture was heated to reflux with removal of ethanol by Dean-Stark trap. After 3h, the mixture was cooled to room temperature and the precipitate is collected by vacuum filtration. Compound 53 was obtained as a brown solid.

5

Compound 54:

3-Chloro-1-(2-Morpholin-4-yl-ethyl)-1H -quinoxalin-2-one



10 Compound 54 was obtained as the hydrochloride salt from compound 53 by method B.

Compound 55:

N-Isoxazol-3-yl-4-[4-(2-Morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino]-benzamide

PRD-2174

5

Compound 55 was obtained from compound 54 and 4-amino-N-isoxazol-3yl-benzamide by method C as a trifluoroacetic acid salt after purification by reverse phase HPLC. ¹H NMR (DMSO) δ 11.30 (s, 1H), 9.87 (s, 1H), 8.86 (d, J=1.7 Hz, 1H), 8.36 (d, J=8.9 Hz, 2H), 8.07 (d, J=8.9 Hz, 2H), 7.71 (dd, J= 7.5, 1.8 Hz, 1H), 7.50 (d, J= 8.3 Hz, 1H), 7.48-7.37 (m, 2H), 7.08 (d, J= 1.7 Hz, 1H), 4.73 (m, 2H), 4.15-3.92 (m, 4H), 3.89-3.57 (m, 4H), 3.51-3.21 (m, 2H).

Compound 56:

10 4-[4-(2-morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide

Compound 56 was obtained as a hydrochloride salt from compound 54 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. ¹H NMR (DMSO) δ 10.68 (bs, 1H), 9.76


PRD-2174

(s, 1H), 9.07 (t, J= 5.6 Hz, 1H), 8.29 (d, J= 8.58 Hz, 2H), 7.91 (d, J= 8.58 Hz, 2H), 7.67 (appt, J= 7.5 Hz, 2H), 7.43-7.35 (m, 3H), 7.04 (s, 1H), 6.99-6.95 (m, 1H), 4.77-4.72 (m, 2H), 4.65 (d, J=5.7 Hz, 2H), 4.05-3.95 (m, 2H), 3.78-3.64 (m, 4H), 3.61-3.53 (m, 2H), 3.31-3.24 (m, 2H).

5

Compound 57:

4-[4-(2-morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-benzoic acid methyl ester



10

Compound 57 was obtained as a hydrochloride salt from compound 54 and methyl 4-aminobenzoate by method C.

Compound 58:

4-[4-(2-morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-pyrazol-3-yl-benzamide

PRD-2174

Compound 58 is obtained as a hydrochloride salt from compound 57 and 3-5 aminopyrazole by method D. ¹H NMR (DMSO) δ 10.7 (s, 1H), 10.34 (bs, 1H), 9.8 (s, 1H), 8.31 (d, J=8.9 Hz, 2H), 8.05 (d, J=8.9 Hz, 2H), 7.70-7.66 (m, 3H), 7.45-7.35 (m, 2H), 6.62 (d, J= 2.3 Hz, 1H), 4.76 (appt, J=5.8 Hz, 2H), 4.10-4.03 (m, 4H), 3.76-3.54 (m, 4H), 3.51-3.32 (m, 2H)

10

Compound 59:

(2-Piperidin-1-yl-ethyl)-(2-nitro-phenyl)-amine

15 Compound 59 was obtained as an orange oil from 2-fluoronitrobenzene and 1-(aminoethyl)-piperidine by method H.

Compound 60:

1-(2-Piperidin-1-yl-ethyl)-1,4-dihydro-quinoxaline-2,3-dione

PRD-2174

5

10

Compound 60 was obtained as a gray solid from compound 59 by method I.

Compound 61:

3-Chloro-1-(2-piperidin-1-yl-ethyl)-1H -quinoxalin-2-one

Compound 61 was obtained as a hydrochloride salt from compound 60 by method B.

Compound 62:

4-[4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide

PRD-2174

Compound 62 was obtained as a hydrochloride salt from compound 61 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. ¹H NMR (DMSO) δ 10.38 (bs, 1H), 9.74 (s, 1H), 9.08 (t, J=5.9 Hz, 1H), 8.27 (d, J=8.7 Hz, 2H), 7.90 (d, J=8.7 Hz, 2H), 7.72 (d, J=7.8 Hz, 1H), 7.65 (dd, J=7.6,1.8 Hz, 1H), 7.42-7.33 (m, 3H), 7.03 (d, J=2.6 Hz, 1H), 6.97 (dd, J=4.9, 3.5 Hz, 1H), 4.76 (appt, J=6.5 Hz, 2H), 4.64 (d, J=5.9 Hz, 2H), 3.67 (d, J=11.5 Hz, 2H), 3.39 (d, J=5.8 Hz, 2H), 3.02 (d, J=10.6, 2H), 1.85-1.7 (m, 5H), 1.43-1.38 (m, 1H).

10

15

5

Compound 63:

(2-nitro-phenyl)-(2-pyridin-2-yl-ethyl)-amine

Compound 63 was obtained as an orange oil from 2-(2-aminoethyl)-pyridine and 2-fluoronitrobenzene by method H.

Compound 64:

1-(2-Pyridin-2-yl-ethyl)-1,4-dihydro-quinoxaline-2,3-dione

PRD-2174

Compound 64 was obtained as a gray solid from compound 63 by method I.

Compound 65:

3-Chloro-1-(2-pyridin-2-yl-ethyl)-1H -quinoxalin-2-one

Compound 65 was obtained as a dark solid from compound 64 by method B.

10

5

Compound 66:

4-[4-(2-pyridin-2-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide

PRD-2174

5

10

15

Compound 66 was obtained as a white solid from compound 65 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C. 1 H NMR (DMSO) δ 9.68 (s, 1H), 9.02 (t, J=5.8 Hz, 1H), 8.53 (m, 1H), 8.26 (d, J=8.9 Hz, 2H), 7.88 (d, J=8.7 Hz, 2H), 7.72 (m, 1H), 7.62 (m, 1H), 7.54 (m, 1H), 7.40-7.23 (m, 5H), 7.03 (m, 1H), 6.67 (m, 1H), 4.66 (m, 4H), 3.17 (t, J=7.3 Hz, 2H).

Compound 67:

N,N-Dimethyl-N-(2-nitro-phenyl)-ethane-1,2-diamine

H NO₂

Compound 67 was obtained as an orange oil from 2-fluoronitrobenzene and N,N-dimethyl-ethylenediamine by method H.

Compound 68:

1-(2-dimethylamino-ethyl)-1,4-dihydro-quinoxaline-2,3-dione

WO 2005/067932

PRD-2174

Compound 68 was obtained as a gray solid from compound 67 by method I.

5

Compound 69:

3-Chloro-1-(2-dimethylamino-ethyl)-1H-quinoxalin-2-one

Compound 69 was obtained as a hydrochloride salt from compound 68 by method B.

10

Compound 70:

4-[4-(2-dimethylamino-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide

PRD-2174

Compound 70 was obtained from compound 69 and 4-amino-N-thiophen-2ylmethylbenzamide by method C as a trifluoroacetic acid salt after purification by reverse phase HPLC. 1 H NMR (DMSO) δ 9.76 (s, 1H), 9.20 (bs, 1H), 9.02 (t, J=5.8, 1H), 8.28 (d, J=8.8 Hz, 2H), 7.90 (d, J=8.8 Hz, 2H), 7.65 (dd, J=7.48, 1.9, 1H), 7.56 (d, J=7.89 Hz, 1H), 7.43-7.33 (m, 3H), 7.03 (d, J=2.5 Hz, 1H), 7.03 (d, J=2.5 Hz, 1H), 6.96 (dd, J= 5, 3.5 Hz, 1H), 4.70 (appt, J=5.6 Hz, 2H), 4.64 (d, J=5.6 Hz, 2H), 3.50 (d, J=4.6 Hz, 2H), 2.97 (s, 3H), 2.95 (s, 3H).

10

5

Compound 71:

(2-Nitro-phenylamino)-acetic acid tert-butyl ester

15 Compound 71 was obtained as an orange oil from 2-fluoronitrobenzene and glycine *tert*-butyl ester by method H.

Compound 72:

(2-Amino-phenylamino)-acetic acid tert-butyl ester

PRD-2174

Compound 72 was obtained as a dark solid from compound 71 by method F.

5 Compound 73:

(2,3-dioxo-3,4-dihydro-2H-quinoxalin-1-yl)-acetic acid tert-butyl ester

Compound 73 was obtained as a white solid from compound 72 by method A.

10

Compound 74:

(3-Chloro-2-oxo-2H-quinoxalin-1-yl)-acetic acid tert-butyl ester

PRD-2174

Compound 74 was obtained as a dark solid from compound 73 by method B.

5 Compound 75:

(2-Oxo-3-{4-[(thiophen-2ylmethyl)-carbamoyl]-phenylamino}-2H-quinoxalin-1-yl)-acetic acid

Compound 75 was obtained as a white solid from compound 74 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C, followed by treatment with trifluoroacetic acid overnight at room temperature. ¹H NMR (DMSO) δ 9.77 (s, 1H), 9.04 (t, J=6.1 Hz, 1H), 8.25 (d, J=8.78 Hz, 2H), 7.90 (d, J=8.78 Hz, 2H), 7.41 (d, J=11.49 Hz, 1H), 7.38-7.30 (m, 4H), 7.04 (appt, J=2.4, 1 Hz, 1H), 6.97 (dd, J=5.1, 3.6 Hz, 1H), 5.09 (s, 2H), 4.65 (d, J=5.75 Hz, 2H).

Compound 76:

PRD-2174

5

15

2-Chloro-3-methoxy-quinoxaline

To a solution of 2,3-dichloro-quinoxaline (500 mg, 2.51 mmol) in THF (5mL) at 0°C was added sodium methoxide (0.57 mL of a 25% solution in methanol, 2.51 mmol) dropwise. The reaction was stirred at 0oc for 30 min then warmed to room temperature or 1h. The reaction mixture was diluted with dichloromethane, washed with brine, dried (MgSO₄), and concentrated *in vacuo* to give compound 76 as a yellow solid.

10 Compound 77:

4-(3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide

Compound 77 was obtained as a white solid from compound 76 by method D. 1 H NMR (DMSO) δ 12.49 (bs, 1H), 9.64 (s, 1H), 9.01 (t, J=5.8 Hz, 1H), 8.26 (d, J=8.8 Hz, 2H), 7.88 (d, J=8.8 Hz, 2H), 7.57-7.54 (m, 1H), 7.38 (m, 1H), 7.28-7.20 (m, 3H), 7.02 (m, 1H), 6.97 (m, 1H), 4.63 (d,J=5.8 Hz, 2H).

Compound 78:

N-Benzyl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide

PRD-2174

5

15

20

Compound 78 was obtained as a white solid from benzylamine and compound 3 by method D. 1 H NMR (DMSO) δ 9.70 (s, 1H), 8.93 (t, J=5.9 Hz, 1H), 8.26 (d, J=9.0 Hz, 2H), 7.92 (d, J=9.0 Hz, 2H), 7.61 (d, J=7.7 Hz, 1H), 7.52-7.21 (m, 8H), 4.49 (d, J=5.9 Hz, 2H), 3.71 (s, 3H).

Biological Example 1

10 Enzyme Inhibition Assay:

In 96-well clear plates, glycogen phosphorylase (from rabbit muscle, Sigma P1261) was incubated in a buffer (50 mM HEPES, pH 7.2, 100 mM KC1, 2.5 mM EGTA, and 2.5 mM MgC1₂) containing 1 mg/ml glycogen, 0.25 mM glucose 1-phosphate, and test compound for 15-30 minutes at room temperature (total volume is 100 mL). All samples contain 2% DMSO, and the background lacks enzyme but contains all substrates. The reaction was stopped by the addition of 150 mL of a 1N HCl solution containing 10 mg/ml ammonium molybdate and 0.38 mg/ml malachite green. After a 15-minute incubation period to allow the colored reaction (a quantitative measurement of inorganic phosphate) to develop, the colored wells were read at 650 nm. Data was reported as percent inhibition (+/- 10%) of enzymatic activity at a specified concentration.

Compound	% inhibition	IC50 (μM, +/05)
4	98% @ 20μ M	0.1
10	100% @ 20μ M	0.11
7	92% @ 20μΜ	0.12
11	99% @ 20μ M	0.12
28	100% @ 20μΜ	0.12
46	72% @ 20μM	0.14
77	98% @ 20μΜ	0.16

PRD-2174

94% @ 20μM 99% @ 20μM 93% @ 20μM 97% @ 20μM 70% @ 20μM	0.19 0.19 0.2 0.26		
93% @ 20μM 97% @ 20μM	0.2		
97% @ 20μΜ			
	0.26		
70% @ 20μM			
	0.28		
99% @ 20μM	0.3		
96% @ 20μ M	0.32		
99% @ 20μM	0.35		
95% @ 20μ M	0.42		
100% @ 20μ M	0.46		
86% @ 20μ M	0.48		
74% @ 20μM	0.58		
96% @ 20μM	0.69		
65% @ 20μM	0.7		
99% @ 20μM	0.7		
93% @ 20μ M	0.71		
92% @ 20μ M	0.73		
97% @ 20μΜ	0.8		
90% @ 20μM	0.83		
95% @ 20μΜ	0.89		
68% @ 20μM	1.3		
70% @ 20μM	1.5		
89% @ 20μΜ	1.8		
82% @ 20μM	2.5		
92% @ 20μM	2.5		
80% @ 20μ M	2.5		
40% @ 20μ M	5		
77% @ 20μM	5		
77% @ 20μM	5.7		
	99% @ 20μM 96% @ 20μM 99% @ 20μM 95% @ 20μM 100% @ 20μM 86% @ 20μM 74% @ 20μM 96% @ 20μM 96% @ 20μM 93% @ 20μM 93% @ 20μM 97% @ 20μM 97% @ 20μM 95% @ 20μM 97% @ 20μM 95% @ 20μM 95% @ 20μM 95% @ 20μM 95% @ 20μM 70% @ 20μM 80% @ 20μM 82% @ 20μM		

PRD-2174

G. Other Embodiments

The advantages and features of the invention will be apparent to one of ordinary skill from the disclosure herein and the appended claims. Other variations, modifications, and adaptations known or within the ability of one of ordinary skill in the art are contemplated as within the scope of the invention as disclosed herein.

10

5


What is claimed is:

PRD-2174

CLAIMS

1. A compound of formula (I):

5



wherein R¹ is H, C₁₋₆ alkyl, or halo;

R² is H or halo;

R³ is H, C₁₋₆ alkyl, X is N or CH;

Y is a covalent bond, -NHCO- or -CONH-;

Z is phenyl or a 5 or 6-membered heterocyclyl with between 1 and 2 heteroatoms

15 independently selected from N, O, and S; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt, ester, amide, hydrate, or solvate thereof.

2. A compound of claim 1, wherein R¹ is H.

- 3. A compound of claim 1, wherein R^2 is H.
- 4. A compound of claim 1, wherein R^3 is H or C ₁₋₃ alkyl.
- 25 5. A compound of claim 1, wherein n is 0 or 1.
 - 6. A compound of claim 1, wherein Y is -CONH-.
- 7. A compound of claim 1, wherein R³ is an alkyl substituted with hydroxy, carboxy,
 30 dimethylamino, piperidinyl, pyridinyl, or morpholinyl.

PRD-2174

8. A compound of claim 1, wherein Z is selected from phenyl, furanyl, thiophenyl, isoxazolyl, pyridazyl, pyrazolyl, N-methyl-pyrazolyl, pyrimidyl, pyrrolyl, N-methyl-pyrrole, imidazolyl, pyridyl, oxazolyl, and thiazolyl.

5

- 9. A compound of claim 8, wherein Z is selected from furanyl, thiophenyl, isoxazolyl, and pyrazolyl.
- 10. A compound of claim 1, wherein R¹ is H; R² is H; and R³ is H or C ₁₋₂ alkyl.

10

- 11. A compound of claim 1, wherein n is 0 or 1; and Y is -CONH-.
- 12. A compound of claim 10, wherein Z is selected from furanyl, thiophenyl, isoxazolyl, pyridazyl, pyrazolyl, pyrimidyl, pyrrolyl, imidazolyl, pyridyl, oxazolyl, and thiazolyl.
- 13. A compound of claim 12, wherein n is 0 or 1.
- 14. A compound selected from:
- 4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethylbenzamide;
 - 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1*H*-pyrazol-3-yl)-benzamide;
 - N-Is oxazol-3-yl-4-[4-(2-Morpholin-4-yl-ethyl)-3-oxo-3, 4-dihydro-quinoxalin-4-yl-ethyl)-3-oxo-3, 4-dihydro-quinoxalin-4-yl-ethyl-
- 25 2ylamino]-benzamide;
 - 4-(4,6-Dimethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethylbenzamide;
 - 4-[4-(2-hydroxy-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide;
- N-Isoxazol-3-yl-4-(4-Methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-benzamide;

PRD-2174

4-[4-(2-morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide; and

4-[4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide.

5

15. A compound selected from:

N-Isoxazol-3-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide; 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethylbenzamide;

N-Isoxazol-5-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide; 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-furan-2-ylmethyl-benzamide;

N-Isoxazol-3-yl-4-(4-Ethyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide; 4-(7-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-

15 ylmethyl-benzamide; and

4-(4-Methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-N-thiophen-2-ylmethyl-benzamide.

16. A compound selected from:

Isoxazole-5-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide;

Isoxazole-3-carboxylic acid [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-amide; and

N- [4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-phenyl]-nicotinamide.

25

17. A compound selected from:

1-Methyl-3-[4-(1H-pyrrol-2-yl)-phenylamino]-1*H*-quinoxalin-2-one; and 3-(4-imidazol-1-yl-phenylamino)-1-methyl-1*H*-quinoxalin-2-one.

PRD-2174

- 18. A compound selected from:
- N-Isoxazol-3-yl-4-(7-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;
- 4-(6-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-
- 5 ylmethyl-benzamide;
 - N-Isoxazol-3-yl-4-(6-Fluoro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;
 - N-Isoxazol-3-yl-4-(6-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;
- N-Isoxazol-3-yl-4-(7-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;
 - 4-(6-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-ylmethyl-benzamide;
 - 4-(7-Chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-
- 15 ylmethyl-benzamide;
 - N-Isoxazol-3-yl-4-[4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino]-benzamide;
 - 4-(4-Ethyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-N-thiophen-2-ylmethyl-benzamide;
- N-Isoxazol-3-yl-4-(4-ethyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-ylamino)-benzamide;
 - N-Isoxazol-3-yl-4-[7-fluoro-4-(2-Morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino]-benzamide;
 - 4-[7-Fluoro-4-(2-piperidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-
- 25 thiophen-2-ylmethyl-benzamide;
 - $\hbox{$4$-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-oxazol-2-yl-benzamide;}$
 - N-Furan-2-yl-4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;
 - $\hbox{$4$-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-thiophen-2-yl-benzamide;}$
 - 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1H-pyrrol-3-yl)-
- 30 benzamide;

PRD-2174

4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(1-methyl-1*H*-pyrrol-3-yl)-benzamide;

- 4-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-N-(pyrimidin-2-yl)-benzamide;
- 5 N-(1*H*-Imidazol-2-yl)-4-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-benzamide;
 - 4-[4-(2-pyrrolidin-1-yl-ethyl)-3-oxo-3,4-dihydro-quinoxalin-2ylamino)]-N-thiophen-2-ylmethyl-benzamide; and
 - N-Isoxazol-3-ylmethyl-4-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylamino)-
- benzamide.

- 19. A pharmaceutical composition, comprising a compound of claim 1, 14, 15, 16, 17, or 18 and a pharmaceutically acceptable carrier.
- 20. A method for treating diabetes, said method comprising administering to a patient in need of treatment an effective amount of a pharmaceutical composition, said composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 20 21. A method of claim 20, wherein said diabetes is Type I or Type II diabetes.
 - 22. A method for treating obesity, said method comprising administering to a patient in need of treatment an effective amount of a pharmaceutical composition, said composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/043409

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/498 A61K A61K31/4985 C07D403/12 C07D417/12 C07D413/12 C07D471/04 C07D241/44 A61P3/10 C07D409/12 CO7D407/12 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) A61K C07D A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data, BIOSIS C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category 6 1-22 Α WO 01/23389 A (NEUROGEN) 5 April 2001 (2001-04-05) the whole document WO 00/42026 A (NOVO NORDISK) 1-22 Α 20 July 2000 (2000-07-20) the whole document WO 99/46260 A (ASTRA) 1-22 Α 16 September 1999 (1999-09-16) the whole document 1-22 WO 95/09159 A (OTSUKA) Α 6 April 1995 (1995-04-06) the whole document Patent family members are listed in annex. Further documents are listed in the continuation of box C. ° Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docudocument referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means in the art. document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 6 April 2005 14/04/2005 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Cortés, J

International application No. PCT/US2004/043409

INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 20-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/043409

Patent document		Publication		Patent family	Publication
cited in search report		date	member(s)		date
WO 0123389	Α	05-04-2001	AU	7738000 A	30-04-2001
			BG	106508 A	28-02-2003
			CA	2379640 A1	05-04-2001
			CN	1377356 A	30-10-2002
			CZ	20021086 A3	16-10-2002
			ΕP	1224187 A2	24-07-2002
			HU	0202636 A2	28-12-2002
			JP	2003510327 T	18-03-2003
			NO	20021358 A	27-05-2002
			NZ	517575 A	30-04-2004
			PL	354784 A1	23-02-2004
			WO	0123389 A2	05-04-2001
			ÜS	2003158197 A1	21-08-2003
			ÜS	6506762 B1	14-01-2003
			ÜS	2004229870 A1	18-11-2004
			ZA	200202518 A	30-06-2003
WO 0042026	Α	20-07-2000	ΑU	3033500 A	01-08-2000
			WO	0042026 A1	20-07-2000
			EP	1147094 A1	24-10-2001
			JP	2002534512 T	15-10-2002
W0 9946260	A	16-09-1999	AU	2863899 A	27-09-1999
	• •		WO	9946260 A1	16-09-1999
WO 9509159	Α	06-04-1995	ΑU	674613 B2	02-01-1997
			ΑU	7666094 A	18-04-1995
			CA	2150345 A1	06-04-1995
			CN	1114834 A	10-01-1996
			EP	0670831 A1	13-09-1995
			WO	9509159 A1	06-04-1995
			JP	2759257 B2	28-05-1998
			JP	8012579 A	16-01-1996